Irritable Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 204 Published: September 30, 2021 Report Code: GMDGDHC13077IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome – Drugs In Development, 2021, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 11, 1, 15, 8 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • 4D Pharma Plc

    AbbVie Inc

    Ardelyx Inc

    AsiaBiome

    Assembly Biosciences Inc

    Axim Biotechnologies Inc

    Bausch Health Companies Inc

    Biomica

    Blue Therapeutics Inc

    Boston Pharmaceuticals Inc

    CB2 Therapeutics Inc

    CinRx Pharma LLC

    ConSynance Therapeutics Inc

    Cosmo Pharmaceuticals NV

    Dong-A ST Co Ltd

    Eisai Co Ltd

    Emyria Ltd

    Exeliom Biosciences SAS

    GEXVal Inc

    HK inno.N Corp

    IGY Immune Technologies & Life Sciences Inc

    ImmuneBiotech AB

    Immunic Inc

    Ironwood Pharmaceuticals Inc

    ISOThrive Inc

    Jiangsu Aosaikang Pharmaceutical Co Ltd

    Metacrine Inc

    MGC Pharmaceuticals Ltd

    Napo Pharmaceuticals Inc

    Neurocrine Biosciences Inc

    Nexpharm Korea Co Ltd

    Novome Biotechnologies Inc

    Orphomed Inc

    Oxford Cannabinoid Technologies Ltd

    PeptiDream Inc

    Protagonist Therapeutics Inc

    RaQualia Pharma Inc

    RedHill Biopharma Ltd

    Renexxion LLC

    Seed Health Inc

    Serenity Bioworks Inc

    Serentrix LLC

    Servatus Ltd

    TenNor Therapeutics Ltd

    Velicept Therapeutics Inc

    Virios Therapeutics

  • Inc

    Vitality Biopharma Inc

    Zhiyi Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Irritable Bowel Syndrome – Overview

Irritable Bowel Syndrome – Therapeutics Development

Irritable Bowel Syndrome – Therapeutics Assessment

Irritable Bowel Syndrome – Companies Involved in Therapeutics Development

Irritable Bowel Syndrome – Drug Profiles

Irritable Bowel Syndrome – Dormant Projects

Irritable Bowel Syndrome – Discontinued Products

Irritable Bowel Syndrome – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Irritable Bowel Syndrome – Pipeline by 4D Pharma Plc, 2021

Irritable Bowel Syndrome – Pipeline by AbbVie Inc, 2021

Irritable Bowel Syndrome – Pipeline by Ardelyx Inc, 2021

Irritable Bowel Syndrome – Pipeline by AsiaBiome, 2021

Irritable Bowel Syndrome – Pipeline by Assembly Biosciences Inc, 2021

Irritable Bowel Syndrome – Pipeline by Axim Biotechnologies Inc, 2021

Irritable Bowel Syndrome – Pipeline by Bausch Health Companies Inc, 2021

Irritable Bowel Syndrome – Pipeline by Biomica, 2021

Irritable Bowel Syndrome – Pipeline by Blue Therapeutics Inc, 2021

Irritable Bowel Syndrome – Pipeline by Boston Pharmaceuticals Inc, 2021

Irritable Bowel Syndrome – Pipeline by CB2 Therapeutics Inc, 2021

Irritable Bowel Syndrome – Pipeline by CinRx Pharma LLC, 2021

Irritable Bowel Syndrome – Pipeline by ConSynance Therapeutics Inc, 2021

Irritable Bowel Syndrome – Pipeline by Cosmo Pharmaceuticals NV, 2021

Irritable Bowel Syndrome – Pipeline by Dong-A ST Co Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Eisai Co Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Emyria Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Exeliom Biosciences SAS, 2021

Irritable Bowel Syndrome – Pipeline by GEXVal Inc, 2021

Irritable Bowel Syndrome – Pipeline by HK inno.N Corp, 2021

Irritable Bowel Syndrome – Pipeline by IGY Immune Technologies & Life Sciences Inc, 2021

Irritable Bowel Syndrome – Pipeline by ImmuneBiotech AB, 2021

Irritable Bowel Syndrome – Pipeline by Immunic Inc, 2021

Irritable Bowel Syndrome – Pipeline by Ironwood Pharmaceuticals Inc, 2021

Irritable Bowel Syndrome – Pipeline by ISOThrive Inc, 2021

Irritable Bowel Syndrome – Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Metacrine Inc, 2021

Irritable Bowel Syndrome – Pipeline by MGC Pharmaceuticals Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Napo Pharmaceuticals Inc, 2021

Irritable Bowel Syndrome – Pipeline by Neurocrine Biosciences Inc, 2021

Irritable Bowel Syndrome – Pipeline by Nexpharm Korea Co Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Novome Biotechnologies Inc, 2021

Irritable Bowel Syndrome – Pipeline by Orphomed Inc, 2021

Irritable Bowel Syndrome – Pipeline by Oxford Cannabinoid Technologies Ltd, 2021

Irritable Bowel Syndrome – Pipeline by PeptiDream Inc, 2021

Irritable Bowel Syndrome – Pipeline by Protagonist Therapeutics Inc, 2021

Irritable Bowel Syndrome – Pipeline by RaQualia Pharma Inc, 2021

Irritable Bowel Syndrome – Pipeline by RedHill Biopharma Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Renexxion LLC, 2021

Irritable Bowel Syndrome – Pipeline by Seed Health Inc, 2021

Irritable Bowel Syndrome – Pipeline by Serenity Bioworks Inc, 2021

Irritable Bowel Syndrome – Pipeline by Serentrix LLC, 2021

Irritable Bowel Syndrome – Pipeline by Servatus Ltd, 2021

Irritable Bowel Syndrome – Pipeline by TenNor Therapeutics Ltd, 2021

Irritable Bowel Syndrome – Pipeline by Velicept Therapeutics Inc, 2021

Irritable Bowel Syndrome – Pipeline by Virios Therapeutics, Inc, 2021

Irritable Bowel Syndrome – Pipeline by Vitality Biopharma Inc, 2021

Irritable Bowel Syndrome – Pipeline by Zhiyi Pharmaceuticals Inc, 2021

Irritable Bowel Syndrome – Dormant Projects, 2021

Irritable Bowel Syndrome – Dormant Projects, 2021 (Contd..1)

Irritable Bowel Syndrome – Dormant Projects, 2021 (Contd..2)

Irritable Bowel Syndrome – Dormant Projects, 2021 (Contd..3)

Irritable Bowel Syndrome – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.